Recent progress in development of dopamine receptor subtype-selective agents: Potential therapeutics for neurological and psychiatric disorders

被引：336

作者：

Zhang, Ao ^{[1
]}

Neumeyer, John L.

Baldessarini, Ross J.

机构：

[1] Chinese Acad Sci, Shanghai Inst Mat Med, Bioorgan & Med Chem Lab, Shanghai 201203, Peoples R China

[2] Harvard Univ, Sch Med, McLean Hosp, Med Chem Lab, Belmont, MA 02478 USA

[3] Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA

[4] Harvard Univ, Sch Med, Program Neurosci, Belmont, MA 02178 USA

[5] McLean Hosp, Neuropharmacol Lab, Belmont, MA 02478 USA

来源：

CHEMICAL REVIEWS | 2007年 / 107卷 / 01期

关键词：

D O I：

10.1021/cr050263h

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

This review covers progress during 2000-2005 on the development of selective ligands targeting mainly to the five main dopamine (DA) receptors. Topics discussed include the pharmacology of dopamine receptor subtypes and the development of dopamine receptor subtype ligands. As for the latter, emphasis is on the receptor-selective ligands from D1 to D4. Generally, recent efforts in medicinal chemistry and neuropharmacology have yielded substantial numbers of compounds with activity and selectivity at each of these major DA receptors.

引用

收藏

页码：274 / 302

页数：29

相关论文

共 254 条

[1] Do we still believe in the dopamine hypothesis? New data bring new evidence [J].

Abi-Dargham, A .

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 :S1-S5

[2] The 5-HT1A receptor agonist Bay X 3702 inhibits apoptosis induced by serum deprivation in cultured neurons [J].

Ahlemeyer, B ;

Glaser, A ;

Schaper, C ;

Semkova, I ;

Krieglstein, J .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 370 (02) :211-216

[3] In vivo intrinsic efficacy of the 5-HT1A receptor antagonists NAD-299, WAY-100,635 and (S)-(-)-UH-301 at rat brain monoamine receptors [J].

Ahlenius, S ;

Henriksson, I ;

Magnusson, O ;

Salmi, P .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1999, 9 (1-2) :15-19

[4] Synthesis and binding affinity of novel 3-aminoethyl-1-tetralones, potential atypical antipsychotics [J].

Alvarado, M ;

Coelho, A ;

Masaguer, CF ;

Raviña, E ;

Brea, J ;

Padín, JF ;

Loza, MI .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (12) :3063-3066

[5] Syntheses of dopaminergic 1-cyclohexylmethyl-7,8-dioxygenated tetrahydroisoquinolines by selective heterogeneous tandem hydrogenation [J].

Andreu, I ;

Cabedo, N ;

Torres, G ;

Chagraoui, A ;

de Arellano, MCR ;

Gil, S ;

Bermejo, A ;

Valpuesta, M ;

Protais, P ;

Cortes, D .

TETRAHEDRON, 2002, 58 (51) :10173-10179

[6] Preparation of dopaminergic N-alkyl-benzyltetrahydroisoquinolines using a 'one-pot' procedure in acid medium [J].

Andreu, I ;

Cortes, D ;

Protais, P ;

Cassels, BK ;

Chagraoui, A ;

Cabedo, N .

BIOORGANIC & MEDICINAL CHEMISTRY, 2000, 8 (05) :889-895

[7] Synthesis and biological evaluation of new 4-arylpiperidines and 4-aryl-4-piperidinols:: Dual Na+ and Ca2+ channel blockers with reduced affinity for dopamine D2 receptors [J].

Annoura, H ;

Nakanishi, K ;

Uesugi, P ;

Fukunaga, A ;

Imajo, S ;

Miyajima, A ;

Tamura-Horikawa, Y ;

Tamura, S .

BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (02) :371-383

[8]

[Anonymous], [No title captured]

[9] Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence [J].

Arnt, J ;

Skarsfeldt, T .

NEUROPSYCHOPHARMACOLOGY, 1998, 18 (02) :63-101

[10] The first asymmetric synthesis of a dopamine D1 agonist, dihydrexidine, employing asymmetric conjugate addition technology [J].

Asano, Y ;

Yamashita, M ;

Nagai, K ;

Kuriyama, M ;

Yamada, K ;

Tomioka, K .

TETRAHEDRON LETTERS, 2001, 42 (48) :8493-8495

← 1 2 3 4 5 6 7 8 9 10 →